stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) Return on equity
Maravai LifeSciences Holdings, Inc.'s return on equity over the twelve months to 30 September 2026 was −17.0%, up 10.5 percentage points from fiscal 2025 (−27.5%). Over the past ten years it has ranged from −27.5% (fiscal 2025) to 52.0% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of −52.0% and above the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −27.5% | (6.34) |
| FY2024 | −21.2% | (7.15) |
| FY2023 | −14.0% | (44.40) |
| FY2022 | 30.4% | (21.64) |
| FY2021 | 52.0% | 0.63 |
| FY2020 | 51.4% | 54.42 |
| FY2019 | −3.05% | 0.09 |
| FY2018 | −3.14% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 18.7% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| SRPT Sarepta Therapeutics, Inc. compare | −8.05% |
| MRVI Maravai LifeSciences Holdings, Inc. | −17.0% |
| TRVI Trevi Therapeutics, Inc. compare | −19.7% |
| VIR Vir Biotechnology, Inc. compare | −21.8% |
| MAZE Maze Therapeutics, Inc. compare | −37.4% |
| REPL Replimune Group, Inc. compare | −115.8% |
| Biotechnology industry median | −52.0% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)